Analysis of Gal-3 expression across multiple RNA sequencing public datasets, combined with data from the GEPIA website, revealed significantly elevated RNA expression levels of Gal-3 in various tumor types, including colon cancer, diffuse large B-cell lymphoma, glioma, kidney cancer, liver cancer, pancreatic cancer, rectal adenocarcinoma, thyroid cancer, gastric cancer, and thymoma, compared with normal tissues (Fig. 1A). This evidence concerns the gene LGALS3 and liver cancer.